Navigation Links
Matthew Lehman of SPRI Clinical Trials Speaks On Designing Trials For Success At The Trout Group Investor Relations Seminar
Date:6/18/2009

NEW YORK, June 18 /PRNewswire/ -- In designing and conducting clinical trials, it is critical to meet FDA objectives while preventing program "drift," according to Matthew Lehman, chief operating officer of SPRI Clinical Trials-Global, LLC in his remarks at a recent seminar for biotechnology companies.

Lehman spoke on "Designing Trials for Success: Balancing FDA Expectations and Operational Reality," at the Trout Group Investor Relations Seminar: Management's Guide to Wall Street, held recently in Munich, Germany. He addressed CEOs and CFOs from private and small and mid-cap life science companies.

The FDA and other regulators are the gatekeepers to realizing shareholder value and future profits, Lehman said. FDA goals of drug safety, efficacy and economic cost/benefit are consistent with those of the other key stakeholders in the drug development process: patients, clinicians and payors. To maximize long term shareholder value, companies must conduct research that is scientifically and statistically valid, clinically meaningful, and that optimizes the use of capital from a time and effectiveness standpoint, he said.

To meet FDA objectives for clinical trials, companies must assure patient safety and evaluate efficacy with validated, clinically meaningful endpoints and statistical significance for the study, Lehman said.

"The FDA expects good science and good medicine. Meetings are serious, specific and formal and should have a defined purpose," he said. "Reviewers want to speak scientist to scientist. Companies should deliver reasoned proposals and obtain yes/no answers."

Although it should be simple to secure agreement with the FDA and then follow through on a development plan, competing interests and operational realities can take programs off track. Management and shareholders need to be aware of this "program drift" and plan accordingly, Lehman said.

'/>"/>
SOURCE SPRI Clinical Trials
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. USP Names Matthew Heyman Vice President of External Affairs and Strategic Integration
2. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
4. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
5. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
6. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
7. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
8. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
9. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
10. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
11. Caliper Life Sciences to Present at Lehman Brothers Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Pharmaco-Kinesis Corporation (PKC) announced today that its ... on the Beach in Santa Monica, CA ... Company,s innovative Metronomic Biofeedback Pump (MBP), a fully smart ... time to a target site of the human body ... in real-time.  ...
(Date:5/26/2015)... JERUSALEM , May 26, 2015 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has submitted the study protocol for the company,s ... to the U.S. Food and Drug Administration (FDA). The ... Drug (IND) application. The Phase IIb study ...
(Date:5/26/2015)... Just the characterization of being a new breakthrough ... not guarantee immediate acceptance. In particular, a new ... failures is often met with significant skepticism. The ... that is often an unappreciated aspect of scientific innovation. ... has found that building acceptance of its new ...
(Date:5/22/2015)... , May 22, 2015  Actavis plc (NYSE: ... U.S. Court of Appeals for the Second Circuit has ... injunction requiring the Company to continue distribution of NAMENDA ... - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO   "While we ... ruling, we intend to continue our strong efforts to ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8
... Healthcare,Technologies, Ltd. (NASDAQ: HCTL ) announced ... from the Nasdaq Stock Market indicating that the ... 4320(e)(2)(E)(i) (the,"Bid Price Rule") because the closing bid ... below $1.00 per share for 30 consecutive trading ...
... Dec. 13 Patients treated with drug-eluting,stents must ... drug,clopidogrel for at least one year, and possibly ... in a guideline update published,online today in the ... (SCAI), American College of Cardiology (ACC), and,American Heart ...
... Life Sciences,Greenhouse (PLSG), the organization providing capital ... services to the region,s,life sciences enterprises, announced ... ParentPlus was formed to commercialize innovative and,proprietary ... better odds of fulfilling their dream to ...
Cached Biology Technology:Healthcare Technologies, Ltd. Receives Notice From Nasdaq 2PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 2PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 3PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 4The Pittsburgh Life Sciences Greenhouse Invests $100,000 in ParentPlus 2
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... who are confident, comfortable and flexible with their eating ... cardiovascular disease than people who are not. Researchers at ... understand their eating habits could prove to be an ... if people were at higher risk of developing cardiovascular ...
... The Georgia Institute of Technology and Emory University have ... to establish "The Origins Project," a center for integrated ... that may have led to the origin of life. ... in Atlanta and Jackson State University in Mississippi. ...
... plants or animals) that we consume on a daily basis ... or antibiotics. A doctoral thesis carried out by Jorge Juan ... of Analytical Chemistry , at the University of Granada (Universidad ... professors Ana Mara Garc a Campaa and Laura G miz ...
Cached Biology News:Eating competence may lower risk of heart disease 2Georgia Tech/Emory Center to study origin of life 2Alternative methods proposed to detect pesticides and antibiotics in water and natural food 2
Mitochondria/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
... the autofluorescent pigment lipofuscin accumulates in ... including neurons. The presence of lipofuscin ... fluorescence microscopy in the central nervous ... and emission spectra, which overlaps with ...
... belongs to the family of calcium binding proteins ... is composed of an alpha and beta chain ... S100 protein is also expressed in the ... in skin and interdigitating reticulum cells in the ...
LEAF™ Purified anti-human/mouse/rat ICOS...
Biology Products: